Neramexane mesylate clinical trials
A product of Neramexane; its studies count on that page too.
How each study uses neramexane mesylate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Neramexane mesylate
- 7
Studies by the year they started
7 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2008 | 4 |
| 2009 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Neramexane
Studies
Open first, then newest update. How each study uses neramexane mesylate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective TinnitusCompletedPhase 3Merz Pharmaceuticals GmbHNCT00739635Written as Neramexane mesylate
- Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective TinnitusCompletedPhase 3Merz Pharmaceuticals GmbHNCT00955799Written as Neramexane mesylate
- Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective TinnitusTerminatedPhase 3Merz Pharmaceuticals GmbHNCT00827008Written as Neramexane mesylate
- Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective TinnitusCompletedPhase 3Merz Pharmaceuticals GmbHNCT00772980Written as Neramexane mesylate
- Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired NystagmusTerminatedPhase 2Merz Pharmaceuticals GmbHNCT00799942Written as Neramexane mesylate
- Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy VolunteersCompletedPhase 1Merz Pharmaceuticals GmbHNCT00712283Written as Neramexane mesylate
- Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired NystagmusCompletedPhase 2Merz Pharmaceuticals GmbHNCT00661440Written as Neramexane mesylate
Codes
What other systems call neramexane mesylate · ClinicalTrials.gg INT015890
- UNII (FDA) 9M85GXG84DNERAMEXANE MESYLATEConfirmed FDA, Wikidata
- Wikidata Q27272733neramexane mesylateConfirmed FDA, Wikidata
- NCI Thesaurus C75163Neramexane MesylateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 9M85GXG84D | NERAMEXANE MESYLATE | Confirmed FDA, Wikidata |
| Wikidata | Q27272733 | neramexane mesylate | Confirmed FDA, Wikidata |
| NCI Thesaurus | C75163 | Neramexane Mesylate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.